<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03525002</url>
  </required_header>
  <id_info>
    <org_study_id>DopamineGenetics01</org_study_id>
    <nct_id>NCT03525002</nct_id>
  </id_info>
  <brief_title>Dopamine Action on Metabolism in Relation to Genotype</brief_title>
  <official_title>Dopamine Action on Metabolism Depending on Genetic Heterogeneity - a Randomized, Placebo-controlled Double Blind Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital Tuebingen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital Lübeck</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital Tuebingen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Obesity is a widespread disease with increasing prevalence and associated with serious&#xD;
      secondary complications. So far, the origin of the disease, regardless of an existing&#xD;
      positive energy balance, is not fully understood. In addition to environmental factors, the&#xD;
      genetic background plays an important role in the pathogenesis of obesity. Of common genetic&#xD;
      polymorphisms, variants in the fat mass and obesity associated gene (FTO) locus have the&#xD;
      highest effect size on body weight. Animal and first clinical studies indicate that FTO&#xD;
      variants interact with dopamine signaling in the brain, thus influencing the risk of&#xD;
      overweight. In fact, preliminary results indicate that enhancing dopamine signaling with the&#xD;
      dopamine agonist bromocriptine, depending on the FTO genotype, either induces weight loss or&#xD;
      has a neutral effect on body weight.&#xD;
&#xD;
      The planned clinical trial serves to develop a genotype-specific and thus individualized&#xD;
      therapy approach for obesity. The influence of dopamine agonist therapy on weight loss as a&#xD;
      function of the FTO (rs8050136) genotype is to be tested.&#xD;
&#xD;
      Here, the greatest weight loss is expected to occur in subjects carrying the homozygous&#xD;
      risk-allele (AA).&#xD;
&#xD;
      So far, there are only a few established conservative therapy forms of obesity, so that&#xD;
      bariatric interventions with an increasing rate are necessary to achieve weight loss and thus&#xD;
      a reduction in overall morbidity and mortality. Among the approved drug therapies for&#xD;
      obesity, bromocriptine is commonly used. In addition, some interventions require injections.&#xD;
      An early, conservative individualized, genotype-specific treatment with little side-effects&#xD;
      would enable simple treatment of obesity.&#xD;
&#xD;
      Study design: 150 obese (BMI &gt; 30) subjects (50 / study center) will be enrolled in the&#xD;
      study. The subjects will be stratified according to their FTO genotype (rs8050136). Subjects&#xD;
      will be randomized into placebo or bromocriptine treatment group. Treatment will last for 18&#xD;
      weeks and a follow-up will be performed 30 weeks after baseline.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 3, 2018</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>double-blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Interaction between FTO genotype and treatment on change in body weight.</measure>
    <time_frame>18 weeks</time_frame>
    <description>Interaction between FTO (single nucleotide peptide) SNP rs8050136 genotype and treatment (bromocriptine or placebo) on change in body weight.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on body weight</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on dietary intake</measure>
    <time_frame>18 weeks</time_frame>
    <description>Dietary intake will be monitored by food diaries</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on processing of food cues in the brain</measure>
    <time_frame>18 weeks</time_frame>
    <description>Processing of food cues in the brain will be assessed by functional magnetic resonance imaging before and after treatment with bromocriptine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on body fat distribution</measure>
    <time_frame>18 weeks</time_frame>
    <description>Body fat distribution will be assessed by magnetic resonance imaging and magnetic resonance spectroscopy before and after treatment with bromocriptine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on whole body insulin sensitivity</measure>
    <time_frame>18 weeks</time_frame>
    <description>Whole body insulin sensitivity will be quantified from 5 point 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on insulin secretion</measure>
    <time_frame>18 weeks</time_frame>
    <description>Insulin secretion will be quantified from 5 point 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on glucose tolerance</measure>
    <time_frame>18 weeks</time_frame>
    <description>Glucose tolerance will be assessed by 75g oral glucose tolerance test before and after treatment with bromocriptine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on brain insulin sensitivity</measure>
    <time_frame>18 weeks</time_frame>
    <description>Brain insulin sensitivity will be assessed by functional magnetic resonance imaging combined with intranasal insulin administration before and after treatment with bromocriptine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on resting energy expenditure</measure>
    <time_frame>18 weeks</time_frame>
    <description>Resting energy expenditure will be assessed by indirect calorimetry before and after treatment with bromocriptine or placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on physical activity</measure>
    <time_frame>18 weeks</time_frame>
    <description>Physical activity will be monitored using an accelerometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of bromocriptine vs. placebo on serum prolactin concentrations</measure>
    <time_frame>18 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>FTO SNP rs8050136 (AA), Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with FTO SNP rs8050136 AA receiving matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTO SNP rs8050136 (AA), Bromocriptine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with FTO SNP rs8050136 AAreceiving Bromocriptine up to 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTO SNP rs8050136 (CA), Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with FTO SNP rs8050136 CA receiving matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTO SNP rs8050136 (CA), Bromocriptine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with FTO SNP rs8050136 CA receiving Bromocriptine up to 5 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTO SNP rs8050136 (CC), Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants with FTO SNP rs8050136 CC receiving matching Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FTO SNP rs8050136 (CC), Bromocriptine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants with FTO SNP rs8050136 CC receiving Bromocriptine up to 5 mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bromocriptine</intervention_name>
    <description>In each FTO genotype group participants will be randomly receive bromocriptine or placebo.</description>
    <arm_group_label>FTO SNP rs8050136 (AA), Bromocriptine</arm_group_label>
    <arm_group_label>FTO SNP rs8050136 (CA), Bromocriptine</arm_group_label>
    <arm_group_label>FTO SNP rs8050136 (CC), Bromocriptine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>In each FTO genotype group participants will be randomly receive bromocriptine or placebo.</description>
    <arm_group_label>FTO SNP rs8050136 (AA), Placebo</arm_group_label>
    <arm_group_label>FTO SNP rs8050136 (CA), Placebo</arm_group_label>
    <arm_group_label>FTO SNP rs8050136 (CC), Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body mass index (BMI) between &gt;30 kg/m².&#xD;
&#xD;
          -  Understand and voluntarily sign an informed consent document prior to any study&#xD;
             related assessments/procedures.&#xD;
&#xD;
          -  Females of childbearing potential (FCBP) must agree to utilize a reliable form of&#xD;
             contraception simultaneously or practice complete abstinence from heterosexual contact&#xD;
             while participating in the study.&#xD;
&#xD;
          -  Males must agree to use a latex condom during any heterosexual contact while&#xD;
             participating in the study and to refrain from donating semen or sperm while&#xD;
             participating in this study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Women during pregnancy and lactation.&#xD;
&#xD;
          -  History of hypersensitivity to the investigational medicinal product or to any drug&#xD;
             with similar chemical structure or to any excipient present in the pharmaceutical form&#xD;
             of the investigational medicinal products.&#xD;
&#xD;
          -  Participation in other clinical trials or observation period of competing trials up to&#xD;
             30 days prior to this study.&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Treatment with Methyldopa, levodopa, dopamine agonists, metoclopramid, domperidon,&#xD;
             glycerol nitrate, griseofulvin, azol-antimycotic drugs, macrolide-antibiotics,&#xD;
             octreotide, orlistat, tamoxifen, liraglutide&#xD;
&#xD;
          -  Any relevant cardiovascular disease, e.g. myocardial infarction, acute coronary&#xD;
             syndrome, unstable angina pectoris, Percutaneous transluminal coronary angioplasty&#xD;
             (PTCA), heart failure (NYHA III-IV), stroke or transient ischemic attack (TIA)&#xD;
&#xD;
          -  Acute or chronic viral hepatitis or liver cirrhosis&#xD;
&#xD;
          -  Impaired renal function, defined as estimated Glomerular Filtration Rate (eGFR) ≤ 60&#xD;
             ml/min (MDRD formula) as determined during screening.&#xD;
&#xD;
          -  Medical history of cancer and/or treatment for cancer within the last 5 years.&#xD;
&#xD;
          -  Claustrophobia&#xD;
&#xD;
          -  Any other clinically significant major organ system disease at screening such as&#xD;
             relevant gastrointestinal, neurologic, psychiatric, endocrine (i.e. pancreatic),&#xD;
             hematologic, malignant, infection or other major systemic diseases making&#xD;
             implementation of the protocol or interpretation of the study results difficult.&#xD;
&#xD;
          -  Presence of any contraindication for the conduct of an MRI investigation, such as&#xD;
             cardiac pacemakers, ferromagnetic haemostatic clips in the central nervous system,&#xD;
             metallic splinters in the eye, ferromagnetic or electronically operated active devices&#xD;
             like automatic cardioverter defibrillators, cochlear implants, insulin pumps and nerve&#xD;
             stimulators, prosthetic heart valves etc.&#xD;
&#xD;
          -  hyperthyroidism&#xD;
&#xD;
          -  therapy refractary hypertension&#xD;
&#xD;
          -  peripheral arterial disease&#xD;
&#xD;
          -  Parkinson´s disease&#xD;
&#xD;
          -  Known current presence or history of one of the following psychiatric diseases:&#xD;
             depression, mania, anxiety and panic disorder, obsessive-compulsive disorder,&#xD;
             schizophrenia, psychosis, addiction&#xD;
&#xD;
          -  pituitary disease&#xD;
&#xD;
          -  treatment with bromocriptine during 12 month before entering the trial&#xD;
&#xD;
          -  dementia&#xD;
&#xD;
          -  gastric or intestinal ulcer&#xD;
&#xD;
          -  Persons with limited temperature sensation and / or elevated sensitivity to warming of&#xD;
             the body&#xD;
&#xD;
          -  Persons with a hearing disorder or a increased sensitivity for loud noises&#xD;
&#xD;
          -  smoking&#xD;
&#xD;
          -  Refusal to get informed of unexpected detected pathological findings&#xD;
&#xD;
        Any other clinical condition that would jeopardize subjects' safety while participating in&#xD;
        this clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Martin Heni, Prof.</last_name>
    <phone>+49 7071-29 82711</phone>
    <email>martin.heni@med.uni-tuebingen.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospital Cologne</name>
      <address>
        <city>Cologne</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Faust, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Luebeck</name>
      <address>
        <city>Luebeck</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sebastian Schmid, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tuebingen, Department of Internal Medicine IV</name>
      <address>
        <city>Tübingen</city>
        <zip>72076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Heni, MD</last_name>
      <phone>+49 7071 29 82714</phone>
      <email>martin.heni@med.uni-tuebingen.de</email>
    </contact>
    <contact_backup>
      <last_name>Andreas Fritsche, MD</last_name>
      <phone>+49 7071 29 82714</phone>
      <email>andreas.fritsche@med.uni-tuebingen.de</email>
    </contact_backup>
    <investigator>
      <last_name>Stephanie Kullmann, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>May 2, 2018</study_first_submitted>
  <study_first_submitted_qc>May 2, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 15, 2018</study_first_posted>
  <last_update_submitted>August 19, 2021</last_update_submitted>
  <last_update_submitted_qc>August 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bromocriptine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

